Drugs / MVA-BN-PRO
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00629057 | Mar 2008 → Dec 2010 | castration-resistant prostate carcinoma | Bavarian Nordic | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA-BN-PRO | “MVA-BN®-PRO is a candidate prostate cancer immunotherapy product comprised of a highly attenuated non-replicating vaccinia virus” NCT00629057 ↗ |
| Modality | Vaccine | “This trial examines three vaccination regimens of MVA-BN®-PRO:” NCT00629057 ↗ |
| Route | Subcutaneous | “by sc injection” NCT00629057 ↗ |